Jasper Therapeutics, Inc.
JSPRNASDAQHealthcare● Active
$0.47
$-0.02(-5.01%)
Market Cap$7606203
P/E Ratio—
52W High$7.19
52W Low$0.43
Jasper Therapeutics, Inc. (JSPR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JSPR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.38
Est. -$0.46 · +17.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
JSPR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.38 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.46 | -$0.38 | +17.4% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.79 | -$0.32 | +59.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$1.01 | -$1.13 | -11.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$1.20 | -$1.74 | -45.0% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$1.17 | -$1.41 | -20.5% | — | — | — |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$1.27 | -$1.62 | -27.6% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$1.09 | -$1.24 | -13.8% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.38
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.38
EPS Est.
-$0.46
EPS Surpr.
+17.4%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.79
EPS Surpr.
+59.5%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$1.13
EPS Est.
-$1.01
EPS Surpr.
-11.9%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$1.74
EPS Est.
-$1.20
EPS Surpr.
-45.0%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$1.41
EPS Est.
-$1.17
EPS Surpr.
-20.5%
Revenue
—
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$1.62
EPS Est.
-$1.27
EPS Surpr.
-27.6%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$1.24
EPS Est.
-$1.09
EPS Surpr.
-13.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q3 FY2028 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q2 FY2028 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q1 FY2028 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q4 FY2027 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Q3 FY2027 | $-0.60 | $-0.60 | $-0.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +17.4% | $0.92 | $0.96 | +4.23% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +59.5% | $1.05 | $0.90 | -14.29% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -11.9% | $1.78 | $1.78 | +0.00% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -45.0% | $2.85 | $2.97 | +4.21% |
| ▼ Q2 FY2025 | May 12, 2025 | -20.5% | $4.52 | $4.74 | +4.87% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -27.6% | $5.80 | $5.67 | -2.24% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -13.8% | $23.70 | $22.69 | -4.26% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +11.0% | $16.77 | $18.85 | +12.40% |
Q2 FY2026+4.23%
Report Date
May 14, 2026
EPS Beat/Miss
+17.4%
Price Before
$0.92
Price After
$0.96
Q1 FY2026-14.29%
Report Date
Mar 30, 2026
EPS Beat/Miss
+59.5%
Price Before
$1.05
Price After
$0.90
Q4 FY2025+0.00%
Report Date
Nov 10, 2025
EPS Beat/Miss
-11.9%
Price Before
$1.78
Price After
$1.78
Q3 FY2025+4.21%
Report Date
Aug 13, 2025
EPS Beat/Miss
-45.0%
Price Before
$2.85
Price After
$2.97
Q2 FY2025+4.87%
Report Date
May 12, 2025
EPS Beat/Miss
-20.5%
Price Before
$4.52
Price After
$4.74
Q1 FY2025-2.24%
Report Date
Feb 27, 2025
EPS Beat/Miss
-27.6%
Price Before
$5.80
Price After
$5.67
Q4 FY2024-4.26%
Report Date
Nov 7, 2024
EPS Beat/Miss
-13.8%
Price Before
$23.70
Price After
$22.69
Q3 FY2024+12.40%
Report Date
Aug 13, 2024
EPS Beat/Miss
+11.0%
Price Before
$16.77
Price After
$18.85
Avg Beat Reaction+0.78%
Avg Miss Reaction+0.52%
Beat Rate3 / 8 quarters
Largest Move-14.29% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JSPR ends December
Jasper Therapeutics, Inc. (JSPR) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.38 — beating the analyst consensus of $-0.46 by +17.4%. JSPR has beaten EPS estimates for 2 consecutive quarters. The next JSPR earnings date is expected around September 1, 2026.
Each quarter, investors track JSPR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JSPR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JSPR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JSPR earnings · 5 questionsJasper Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. JSPR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JSPR historically reports after market close (AMC).
JSPR earnings datewhen is JSPR earningsJSPR next earnings datewhen does JSPR report earningsJSPR earnings calendar
▸ Source: FMP · Jasper Therapeutics, Inc. SEC filings · US GAAP · Jasper Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026